文献速递心力衰竭与心肌病冠心病

缺血性心力衰竭患者射血分数改善与死亡率的关系

Improvement of ejection fraction and mortality in ischaemic heart failure.
PubMed 文献 · Heart · 2020-08-25

基于STICH试验1212例缺血性心肌病患者,618例完成基线和24个月超声心动图评估。24个月LVEF改善≥10%在CABG联合药物治疗组为19%(58例),单纯药物治疗组为16%(51例),差异无统计学意义(p=0.30)。LVEF改善>10%与全因死亡风险降低独立相关(HR 0.61,95%CI 0.44-0.84,p=0.004)。

要点

  • 缺血性心肌病患者24个月LVEF改善≥10%并不常见,CABG与单纯药物治疗无显著差异。
  • LVEF改善>10%与死亡风险降低独立相关(HR 0.61,95%CI 0.44-0.84)。
  • 既往心肌梗死和较低基线LVEF是LVEF改善>10%的独立预测因素。

核心结论

  • 缺血性心肌病患者24个月LVEF改善≥10%不常见,CABG与单纯药物治疗无差异,且与死亡率降低独立相关。

研究设计与样本

  • STICH试验(NCT00023595)纳入1212例缺血性心力衰竭患者,其中618例完成基线和24个月超声心动图LVEF评估。
  • 比较LVEF改善≥10%与未改善患者的特征,采用logistic回归分析独立预测因素,Cox比例风险模型评估LVEF改善≥10%与死亡率的独立关联。

主要发现

  • CABG联合药物治疗组58例(19%)LVEF改善>10%,单纯药物治疗组51例(16%),差异无统计学意义(p=0.30)。
  • LVEF改善>10%的独立预测因素包括既往心肌梗死(OR 0.44,95%CI 0.28-0.71,p=0.001)和较低基线LVEF(OR 0.94,95%CI 0.91-0.97,p<0.001)。
  • LVEF改善>10%(HR 0.61,95%CI 0.44-0.84,p=0.004)和随机分配至CABG(HR 0.72,95%CI 0.57-0.90,p=0.004)均与死亡风险降低独立相关。

临床怎么用

  • 在缺血性心肌病患者中,动态监测LVEF变化有助于识别死亡风险较高的亚群。
  • LVEF改善>10%可作为预后改善的独立标志,但CABG与药物治疗在LVEF改善率上无显著差异。

局限性

  • 仅618例(约51%)患者完成基线和24个月超声心动图评估,可能存在选择偏倚。
  • LVEF改善的评估依赖于超声心动图,未报告其可重复性或中心间变异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The frequency and predictors of improvement in left ventricular ejection fraction (LVEF) in ischaemic cardiomyopathy and its association with mortality is poorly understood. We sought to assess the predictors of LVEF improvement ≥10% and its effect on mortality. METHODS: We compared characteristics of patients enrolled in The Surgical Treatment for Ischaemic Heart Failure (STICH) trial with and without improvement of LVEF ≥10% at 24 months. A logistic regression model was constructed to determine the independent predictors of LVEF improvement. A Cox proportional hazards model was created to assess the independent association of improvement in LVEF ≥10% with mortality. RESULTS: Of the 1212 patients enrolled in STICH, 618 underwent echocardiographic assessment of LVEF at baseline and 24 months. Of the patients randomised to medical therapy plus coronary artery bypass graft surgery (CABG), 58 (19%) had an improvement in LVEF >10% compared with 51 (16%) patients assigned to medical therapy alone (p=0.30). Independent predictors of LVEF improvement >10% included prior myocardial infarction (OR 0.44, 95% CI: 0.28 to 0.71, p=0.001) and lower baseline LVEF (OR 0.94, 95% CI: 0.91 to 0.97, p<0.001). Improvement in LVEF >10% (HR 0.61, 95% CI: 0.44 to 0.84, p=0.004) and randomisation to CABG (HR 0.72, 95% CI: 0.57 to 0.90, p=0.004) were independently associated with a reduced hazard of mortality. CONCLUSIONS: Improvement of LVEF ≥10% at 24 months was uncommon in patients with ischaemic cardiomyopathy, did not differ between patients assigned to CABG and medical therapy or medical therapy alone and was independently associated with reduced mortality. TRIAL REGISTRATION NUMBER: NCT00023595.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Perry AS, Mann DL, Brown DL, et al. Improvement of ejection fraction and mortality in ischaemic heart failure. Heart. 2020. PMID: 32843496. doi:10.1136/heartjnl-2020-316975

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。